VladislavSandler

Co-founder and CEO of @HemogenyxPharma; I share science and business news. All opinions are mine. “kindness to the cruel is cruelty to the kind.”

[VladislavSandler @VMSandler]

@RubinReport @dbongino @TulsiGabbard @FBIDirectorKash

[VladislavSandler @VMSandler]

@EliAfriatISR Golda

[Hemogenyx Pharmaceuticals PLC @HemogenyxPharma]

The team of @HemogenyxPharma always remembers two numbers: 75 and 50. 75 people are diagnosed with #AML and 50 people die of AML each day in the US. We want to drastically reduce mortality caused by #AML Every day we work to save lives and improve the World.

[VladislavSandler @VMSandler]

@EgliDieter Perhaps you will now rethink your support of trump.

[VladislavSandler @VMSandler]

https://t.co/WKVHEKXj3n

[VladislavSandler @VMSandler]

@benno0910 https://t.co/KYYU2dzTDO

[VladislavSandler @VMSandler]

7 is a greatest prime number (below 10).

[Hemogenyx Pharmaceuticals PLC @HemogenyxPharma]

At Hemogenyx Pharmaceuticals, we are committed to pioneering cutting-edge cell and gene therapies. Our state-of-the-art, custom-built facility is designed to meet GMP standards, ensuring high-quality manufacturing of advanced therapeutics.

[VladislavSandler @VMSandler]

@StopAntisemites I would love to see how this lady would say these words to Sandy Weill. Sandy has “steel” and eyes and “stone” jaws, if you know what I mean.

[VladislavSandler @VMSandler]

@TomWinnifrith Since you are writing about the company I co-founded and currently run as a CEO, would you be so kind as to send your writing to my email?
Thank you.

[VladislavSandler @VMSandler]

@VPrasadMDMPH This is an unusually aggressive first salvo in a presumably scientific debate. Why this way rather than a customary fact/data based rebuttal?

[Hemogenyx Pharmaceuticals PLC @HemogenyxPharma]

Hemogenyx Pharmaceuticals Opens First Clinical Site for HG-CT-1 Phase I Trial
Patient Recruitment Begins for CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia in Adults
https://t.co/mS8nr7BHEd

[VladislavSandler @VMSandler]

Listen to this interview, listen carefully https://t.co/cbVH1TDc5c

[VladislavSandler @VMSandler]

CAR T cells keep marching in.

https://t.co/cI1Jt1cBAT

[VladislavSandler @VMSandler]

CD33xflt3 NK cells for R/R AML - just 2 CR patients in phase 1. Both patients are still in remission at 4+ and 3+ days.
380% rise in 2 days

https://t.co/GBlokyciwr

[Hemogenyx Pharmaceuticals PLC @HemogenyxPharma]

Hemogenyx Pharmaceuticals Announces Schedule for Opening First Clinical Site for Phase I Trial of HEMO-CAR-T (HG-CT-1)
https://t.co/9fUJFvTbxa

[Hemogenyx Pharmaceuticals PLC @HemogenyxPharma]

Hemogenyx Pharmaceuticals is featured in the article about biotech in New York City
Inside Harlem’s unlikely ‘life-sciences’ boom

https://t.co/eAm2kKM5FW

[Hemogenyx Pharmaceuticals PLC @HemogenyxPharma]

Hemogenyx Pharmaceuticals is pleased to announce that it has developed a new and improved version of its bi-specific antibody ("CDX") for the treatment of R/R AML, a subset of ALL, and potentially for conditioning in bone marrow transplantations. https://t.co/OXogWiJMrU

[Hemogenyx Pharmaceuticals PLC @HemogenyxPharma]

Hemogenyx Pharmaceuticals PLC Announces Presentation at CBD S&T Conference - BioSpace https://t.co/npasJJAQYC

[VladislavSandler @VMSandler]

@bneiluj I hope you will recover fast, my friend! See you in London!